4729-11-02 Schedule I controlled substances.

 

 

 

4729-11-02                  Schedule I controlled substances.

 

 

 

(A)   The state board of pharmacy hereby schedules the following synthetic cannabinoid compounds as schedule I controlled substance hallucinogens:

 

(1)    PB-22 (chemical name: quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) shall be a schedule I controlled substance;

 

(2)          5-Fluoro-PB-22                        (chemical               name:               quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) shall be a schedule I controlled substance.

 

(B)   Except as otherwise provided in section 3719.41 of the Revised Code, any compound that meets at least three of the following pharmacophore requirements to bind at the CB1 and CB2 receptors, as identified by a report from an established forensic laboratory, is a schedule I controlled substance hallucinogen:

 

(1)   A chemical scaffold consisting of substituted or non-substituted ring structures that facilitate binding of required elements (such as: indole compounds, indazoles, benzimidazoles or other ring types);

 

(2)     Alkyl or aryl side chain off the chemical scaffold providing hydrophobic interaction with the CB1 and CB2 receptors;

 

(3)   Carbonyl or ester or equivalent for hydrogen bonding;

 

(4)   Cyclohexane, naphthalene ring, substituted butanamide or equivalent for steric requirements for CB1 and CB2 receptor binding.

 

(C)   Except as otherwise provided in section 3719.41 of the Revised Code, any compound that contains the structural requirements of the cathinone pharmacophore, as identified by a report from an established forensic laboratory, is a schedule I controlled substance.

 

(D)  Except as otherwise provided in section 3719.41 of the Revised Code, any compound that meets the following fentanyl pharmacophore requirements to bind at the mu receptor, as identified by a report from an established forensic laboratory, is a schedule I controlled substance opiate:

 

(1)   A chemical scaffold consisting of: a five, six or seven member ring structure containing a nitrogen, whether or not further substituted;

 

(a)a five, six or seven member ring structure containing a nitrogen, whether

 

 

or not further substituted; and

(b) An attached nitrogen to the ring, whether or not that nitrogen is enclosed in a ring structure, including an attached aromatic ring or other lipophilic group to that nitrogen;

(2) An attached nitrogen to the ring, whether or not that nitrogen is enclosed in a ring structure, including an attached aromatic ring or other lipophilic group to that nitrogen;

(3)(2) A polar functional group attached to the chemical scaffold, including but not limited to, a hydroxyl, ketone, amide or ester;

(4)(3) An alkyl or aryl substitution off the ring nitrogen of the chemical scaffold; and

(5)(4) The compound has not been approved for medical use by the United States food and drug administration.

(E) 6-monoacetylmorphine  (6-MAM)  is  a  schedule  I  controlled  substance  opium derivative.

(F) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (U-47700) is a schedule I controlled substance opium derivative.

Effective:	06/26/2016
Five Year Review (FYR) Dates:	04/17/2019
CERTIFIED ELECTRONICALLY
Certification
06/16/2016
Date
Promulgated Under:	119.03
Statutory Authority:	3719.44, 3719.28, 4729.26
Rule Amplifies:	3719.44, 3719.41
Prior Effective Dates:	4/17/2014, 1/15/2016